drugset / Trial / NCT06298058
A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.
Phase 1
Recruiting
144 enrolled
Shanghai Institute Of Biological Products
Shanghai Pulmonary Hospital, Shanghai, China · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety, tolerability, and pharmacokinetic characteristics of SIBP-A13 and determine the maximum tolerable dose (MTD) and phase II recommended dose (RP2D).
Timeline
- Start
- 2024-05-09
- Primary completion
- 2026-04-30
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SIBP-A13 | Unknown | 1 mg/kg | Intravenous |
| Subject | SIBP-A13 | Unknown | 2 mg/kg | Intravenous |
| Subject | SIBP-A13 | Unknown | 4 mg/kg | Intravenous |
| Subject | SIBP-A13 | Unknown | 5 mg/kg | Intravenous |
| Subject | SIBP-A13 | Unknown | 6 mg/kg | Intravenous |
| Subject | SIBP-A13 | Unknown | 8 mg/kg | Intravenous |